<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01739777</url>
  </required_header>
  <id_info>
    <org_study_id>UANDES-C4C</org_study_id>
    <secondary_id>CORFO-11IEI-9766</secondary_id>
    <nct_id>NCT01739777</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy</brief_title>
  <acronym>RIMECARD</acronym>
  <official_title>Phase 1 Randomized-Double Blind Clinical Trial of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Transplantation in Heart Failure on Patients With Cardiopathy in Dilated Stage, of Different Etiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Los Andes, Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Los Andes, Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and clinical effectiveness of umbilical
      cord mesenchymal cells transplanted by intravenous infusion in patients with heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I-II Clinical Trial - Safety and efficacy of umbilical cord derived mesenchymal stem
      cells (ucMSC) in patients with heart failure Randomized, double blind, controlled prospective
      study in patients with compensated heart failure in dilated phase.

      Thirty patients will be selected, who will undergo a strict 3-month followup of ventricular
      function before being sequentially randomized into two groups: the first group of 15 patients
      will receive a sole injection of ucMSC and the remaining 15 patients will comprise the
      control group.

      Every patient will maintain their standard treatment of heart failure, with maximum tolerated
      dosage without side effects.

      The day of infusion will be considered day zero. From that moment, followup will be divided
      into 0-3, 3-6, and 6-12 months.

      Clinical results will be analyzed after completion of 12 months of followup.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Change in global left ventricular ejection fraction</measure>
    <time_frame>3, 6, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Change in functional capacity measured in O2 consumption</measure>
    <time_frame>0, 3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Occurrence of major adverse cardiac event</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Change in high sensitivity C-reactive protein (hs CRP)</measure>
    <time_frame>0, 3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Reduction in level of B-type natriuretic peptide (BNP)</measure>
    <time_frame>0, 3, 6, 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Measures of anti &amp; pro inflammatory cytokines profile</measure>
    <time_frame>0-15-90 days</time_frame>
    <description>The cytokine profile we can determinate is Interleukin 1 Beta(IL-1b),Interleukin 6 (IL-6), soluble receptor TNF (TNFRs), tumor necrosis factor(TNF), Interleukin 10 (IL-10), Transforming Growth Factor beta (TGFb), Interferon-gamma (IFNg),Interleukin 17A (IL-17A),Interleukin-4(IL-4) by multiflex flow cytometer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>0-6-12 months</time_frame>
    <description>Measures by specific questionnaire of quality of life:
Minnesota Living with Heart Failure Questionnaire (MLHFQ). Kansas, City Cardiomyopathy Questionnaire (KCCQ)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>ucMSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical cord derived mesenchymal are injected intravenously to Patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous placebo solution are administrated to Patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ucMSC</intervention_name>
    <description>1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma</description>
    <arm_group_label>ucMSC</arm_group_label>
    <other_name>Umbilical Cord Mesenchymal Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Controls</intervention_name>
    <description>Autologous Serum will administrated as placebo</description>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic heart failure patients in dilated stages

          -  Etiologies: dilated cardiomyopathy, chronic hypertensive cardiopathy in dilated stage,
             chronic coronary cardiopathy in dilated stage

          -  Ejection fraction ≤ 40%.

          -  Patients who are stable under optimal medical treatment for a period of at least 3
             months prior to randomization

        Exclusion Criteria:

          -  Severe or persistent heart failure

          -  Recurrent myocardial ischemia

          -  Uncontrolled ventricular tachycardia

          -  Malignant disease (life expectancy of less than one year)

          -  Manifest ventricular asynchrony

          -  Hematologic disease

          -  Recent cerebrovascular disease

          -  Recent acute coronary syndrome

          -  Serum creatinine &gt;2.26 mg/dL (200 umol/L)

          -  Atrial fibrillation without heart rate control in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Bartolucci, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de los Andes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad de los Andes</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <link>
    <url>http://www.uandes.cl/</url>
    <description>Universidad de los Andes.</description>
  </link>
  <reference>
    <citation>Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86. doi: 10.1016/j.jacc.2009.06.055.</citation>
    <PMID>19958962</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>November 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2012</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Los Andes, Chile</investigator_affiliation>
    <investigator_full_name>Jorge Bartolucci</investigator_full_name>
    <investigator_title>Medical director of Celular Therapy</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Adult Stem Cells</keyword>
  <keyword>Umbilical Progenitor Cells</keyword>
  <keyword>Umbilical Cord Stem Cells Allogenic</keyword>
  <keyword>Left Ventricular Function</keyword>
  <keyword>Intravenous Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

